Details for Patent: 5,716,957
✉ Email this page to a colleague
Summary for Patent: 5,716,957
Title: | Method for modifying and resetting the bloodstream prolactin levels of a human subject |
Abstract: | A process for the long term modification and regulation of lipid and glucose metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these being the hallmarks of noninsulin dependent, or Type II diabetes)--by administration to a vertebrate, animal or human, of a dopamine agonist and a prolactin stimulator. The dopamine agonist and prolactin stimulator are administered in daily dosages, respectively, at a time of day dependent on the normal circadian rhythm of fat and lean members of a similar species. Decreases in body fat deposits result by treatment of an obese species on a daily timed sequence based on circadian rhythms of the peak prolactin, or peak prolactin and peak glucocorticosteroid, blood level established for lean insulin sensitive members of a similar species. The dopamine agonist is administered at the time of, or just after the time of peak plasma prolactin concentration found in lean animals of the same species and the prolactin stimulator is administered at a time just before the plasma prolactin rhythm reaches its peak in lean animals. Insulin resistance, and hyperinsulinemia or hyperglycemia, or both, can also be controlled in humans on a long term basis by treatment corresponding to that of the treatment for obesity. The short term daily injections reset hormonal timing in the neural centers of the brain to produce long term effects. |
Inventor(s): | Cincotta; Anthony H. (Andover, MA), Meier; Albert H. (Baton Rouge, LA) |
Assignee: | The Board of Supervisors of Louisiana State and Agricultural and (Baton Rouge, LA) Ergo Research Corporation (Wakefield, RI) |
Application Number: | 08/469,012 |
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 5,716,957
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 5,716,957
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Austria | 174793 | ⤷ Try a Trial | |||
Austria | 227566 | ⤷ Try a Trial | |||
Austria | 249216 | ⤷ Try a Trial | |||
Austria | 290863 | ⤷ Try a Trial | |||
Austria | 391506 | ⤷ Try a Trial | |||
Austria | 440606 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |